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Abstract
 
Neural precursor cells from adults have exceptional proliferative and differentiative capability in
vitro yet respond minimally to in vivo brain injury due to constraining mechanisms that are
poorly defined. We assessed whether cell cycle inhibitors that restrict stem cell populations in
other tissues may participate in limiting neural stem cell reactivity in vivo. The cyclin-dependent
kinase inhibitor, p21
 
cip1/waf1
 
 (p21), maintains hematopoietic stem cell quiescence, and we evaluated
its role in the regenerative response of neural tissue after ischemic injury using the mice deficient
in p21. Although steady-state conditions revealed no increase in primitive cell proliferation in
p21-null mice, a significantly larger fraction of quiescent neural precursors was activated in the
hippocampus and subventricular zone after brain ischemia. The hippocampal precursors migrated
and differentiated into a higher number of neurons after injury. Therefore, p21 is an intrinsic
suppressor to neural regeneration after brain injury and may serve as a common molecular regulator
restricting proliferation among stem cell pools from distinct tissue types.
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Introduction
 
Therapeutic effects of stem cell expansion in vitro and re-
generation in vivo in part depend upon stem cell prolifer-
ation. Understanding the molecular basis for the constraint
of stem cell cycling is critical for rationally determined
strategies to manipulate stem cells therapeutically. As
largely modeled in hematopoiesis, maintenance of mature
cell production requires a cytokine-responsive progenitor
cell pool with prodigious proliferative capacity and a
smaller population of stem cells intermittently feeding
daughter cells into a proliferative compartment. In contrast
to progenitor cells, the stem cell pool itself is relatively
quiescent and cytokine resistant, a state which appears
particularly critical in adults (1). In the central nervous
system (CNS), evidence suggests that the proliferative
pools of adult neural progenitor cell (NPC) are derived
from a quiescent multipotent precursor or neural stem cell
(NSC) (2–6). Given a much lower turnover rate in CNS
(7), the mitotic quiescence may also involve NPC. Perhaps
due to the extraordinary quiescence that cannot be suffi-
ciently stimulated by the signals from damaged tissue, endog-
enous NSCs or NPCs do not produce substantial recovery in
cases of severe injury (8). For example, recent studies
demonstrated that the precursors from subventricular zone
(SVZ) in adult brain can migrate into the injured areas and
participate in the neural repair after stroke (9, 10), but the
replacement appeared to be very limited (11). This suggests
a dominant role of intrinsic inhibitors in suppressing the
proliferation of NSC and NPC after injury. Therefore,
understanding the molecular mediators in cell cycle arrest
underlying neural quiescence may ultimately provide mo-
 
J. Qiu and Y. Takagi contributed equally to this work.
The online version of this article contains supplemental material.
Address correspondence to Tao Cheng, Office ste. 2.42e, Research
Pavilion at The Hillman Cancer Center, 5117 Center Ave., Pittsburgh,
PA 15213-1863. Phone: (412) 623-3249; Fax: (412) 623-7778; email:
chengtao@pitt.edu
 
Abbreviations used in this paper: BrdU, 5-bromodeoxyuridine; CKI,
cyclin-dependent kinase inhibitor; CNS, central nervous system; DCX,
doublecortin; EGF, epidermal growth factor; EIA, enzyme immunoassay;
FGF, fibroblast growth factor; GCL, granule cell layer; HSC, hematopoi-
etic stem cell; MCAO, middle cerebral artery occlusion;
 
 
 
NPC, neural pro-
genitor cell; NSC, neural stem cell; p21, p21
 
cip1/waf1
 
; PCNA, proliferat-
ing cell nuclear antigen; SGZ, subgranular zone; SVZ, subventricular zone;
TUNEL, terminal deoxynucleotidyl transferase–mediated deoxyuridine-
triphosphate nick end labeling. 
p21 and Neural Stem Cells
 
938
lecular targets for enhancing endogenous repair mecha-
nisms after acute and chronic damages.
The cell cycle machinery is negatively controlled by sev-
eral cyclin-dependent kinase inhibitors (CKIs) (12). We
demonstrated previously that the founding member of CKI
families, p21
 
cip1/waf1
 
 (p21), maintains relative quiescence of
the hematopoietic stem cell (HSC) (13, 14). p21 was found
to be expressed at a higher level in individual quiescent hu-
man HSCs than in differentiating progenitor cells, and its
absence resulted in a higher fraction of cycling cells in
HSC-enriched populations. Hypothesizing that p21-medi-
ated quiescence may also be present in neural precursors (we
use “precursors” in our text since the cells cannot be clearly
defined as NSC or NPC in vivo), we examined the role of
p21 in a model of adult neural precursors within the hippo-
campus and the lateral ventricle using genetically engineered
mice deficient in p21 gene expression before and after
ischemic brain injury.
 
Materials and Methods
 
Generation of Homozygous Mice
 
We obtained heterozygous 129/SV p21
 
 
 
/
 
 
 
 mice (15) from the
laboratory of Tyler Jacks (Massachusetts Institute of Technology,
Cambridge, MA) and homozygous 129/SV p53
 
 
 
/
 
 
 
 or 129/SV
p53
 
 
 
/
 
 
 
 
 
mice from Jackson Laboratory under the permission of
the Subcommittee on Research Animal Care of the Massachu-
setts General Hospital. The inbred 129/SV heterozygous p21
 
 
 
/
 
 
 
mice were bred to yield homozygous and wild-type offsprings.
Mice were genotyped by PCR using primers specific for the
wild-type and knockout alleles. The littermates at 8–12 wk of age
from the same 
 
 
 
/
 
 
 
 parents were used in further experiments.
Animal care and experimental protocols complied with NIH
guidelines set forth in The Principles of Laboratory Animal Care.
Before all the operations, mice were anesthetized with 1.5% iso-
flurane in 70% N
 
2
 
O and 30% O
 
2
 
 using a Fluotec 3 vaporizer
(Colonial Medical).
 
Middle Cerebral Artery Occlusion (MCAO)
 
Cerebral ischemia was performed in spontaneously ventilating
mice as described previously (16). Body temperature was main-
tained at 37 
 
 
 
 0.5
 
 
 
C with a heating blanket. (FHC). Regional
cerebral blood flow was measured by laser-Doppler flowmetry
(PF2B; Perimed) (16). The left middle cerebral artery was oc-
cluded with an 8-0 nylon monofilament (Ethicon) coated with a
mixture of silicone resin (Xantopren; Bayer Dental) and a hard-
ener (Elastomer Activator; Bayer Dental) as described (16). 20
min later, the filament was withdrawn and cerebral blood flow
reperfusion was confirmed by laser-Doppler flowmetry. After
these procedures, the mice were kept at 32
 
 
 
C for 2 h. Infarct area
was quantified on sections stained by an image analysis system
(M4; Imaging Research) and calculated by summing the volumes
of each section.
 
Physiology Parameters.
 
In randomly selected animals (
 
n
 
 
 
 
 
3–4/group), mean artery blood pressure were monitored as de-
scribed (16). Arterial blood samples were analyzed for oxygen
(PaO
 
2
 
) and carbon dioxide (PaCO
 
2
 
) before and during ischemia
using a blood gas/pH analyzer (Corning 178; Ciba Corning Di-
agnostics). Physiological parameters were as follows: 111 
 
 
 
 8 and
111 
 
 
 
 12 mmHg for the mean artery blood pressure; 7.44 
 
 
 
0.03 and 7.41 
 
 
 
 0.03 for pH; 30 
 
 
 
 5 and 28 
 
 
 
 3 for PaCO
 
2
 
in p21
 
 
 
/
 
 
 
 and p21
 
 
 
/
 
 
 
 animals, respectively. Regional cerebral
blood flow during middle cerebral artery occlusion (MCAO) and
reperfusion were as follows: 9.7 
 
 
 
 4.0% and 8.8 
 
 
 
 4.3 during
ischemia in p21
 
 
 
/
 
 
 
 and p21
 
 
 
/
 
 
 
, respectively, and 2.2 
 
 
 
 24.3% and
76.9 
 
 
 
 20.1% after ischemia in p21
 
 
 
/
 
 
 
 and p21
 
 
 
/
 
 
 
, respectively
(
 
n
 
 
 
  
 
6/group). Infarct volumes were 11.8 
 
 
 
 4.6 mm
 
3
 
 and 11.4 
 
 
 
2.7 mm
 
3
 
 in p21
 
 
 
/
 
 
 
 and p21
 
 
 
/
 
 
 
, respectively (
 
n
 
 
 
  
 
5/group).
 
RT-PCR for p21 and GAPDH
 
Total RNA was isolated from hippocampus or SVZ with TRIzol
method (Life Technologies). 1 
 
 
 
g RNA was treated with 1 U of
amplification-grade DNase I (Life Technologies) to eliminate re-
sidual genomic DNA and reverse transcribed into first-strand
cDNA with oligo-dT primers and 200 U of Superscript II reverse
transcriptase (Life Technologies). Then the specific primer pair
for mouse p21 (5
 
 
 
-AGCCTGAAGACTGTGATGGG-3
 
 
 
 and
5
 
 
 
-AAAGTTCCACCGTTCTCGG-3
 
 
 
) (17) or mouse GAPDH
(5
 
 
 
-TAAAGGGCATCCTGAGCTACACT-3
 
 
 
 and 5
 
 
 
-TTA-
CTCCTTCGAGGCCATGTAGG-3
 
 
 
) was used to amplify the
first cDNA template. The PCR cycles and temperature condi-
tions were optimized to reflect a linear relationship between the
input template and the final PCR product (p21: 45 s at 94
 
 
 
C, 45 s
at 60
 
 
 
, and 1 min at 72
 
 
 
C for 40 cycles; GAPDH: 30 s at 95
 
 
 
C,
30 s at 55
 
 
 
C, and 1 min at 72
 
 
 
C for 25 cycles). PCR was per-
formed in Peltier Thermal Cycler (PTC-200; MJ Research). 1%
agarose gel was used to display the PCR product, and the relative
density ratio between p21 and GAPDH was analyzed with the
NIH imaging system.
 
5-Bromodeoxyuridine Incorporation In Vivo and 
Stereological Analysis
 
Animals received i.p. injections of 5-bromodeoxyuridine (BrdU;
50 mg/kg, dissolved at 5 mg/ml in PBS [Sigma-Aldrich]). Two
daily injections (two times/day) were given to naive animals or to
operated animals on day 7 and 8 or day 14 and 15 after MCAO.
The animals were killed on day 1 or day 28 after the last BrdU
injection (i.e., on day 9, 16, or 35 after MCAO). For histological
evaluation, the animals were perfused transcardially with 4%
paraformaldehyde in PBS under deep anesthesia, and a stereo-
logical estimation (18) was used to quantify the positive cells.
BrdU-positive cells were counted in the dentate gyrus in four
sections per animal (one of every fifteenth serial, 40-
 
 
 
m sections)
throughout the rostro caudal extent of the granule cell layer
(GCL) using a 100
 
 
 
 objective. The GCL area (mm
 
2
 
) was mea-
sured on adjacent sections stained with cresyl violet. The total
granule cell volume (mm
 
3
 
) was estimated by summing the traced
areas for each section multiplied by the distance between sampled
sections. The number of BrdU-labeled cells per mm
 
3
 
 was then
calculated from the sectional and total volumes of the GCL. The
identical stereological approach was applied to examine BrdU in-
corporation in the SVZ (19, 20).
 
Immunohistochemistry Staining
 
Immunohistochemistry was performed on 40-
 
 
 
m floating coro-
nal sections pretreated by denaturing DNA as reported previously
(21). We used mouse anti-BrdU (Becton Dickinson) 1:400 for
DAB staining or rat anti-BrdU ascites fluid (Harlan Sera-Lab),
1:100 for double fluorescence labeling; 1:1,000 for rabbit GFAP
antibody cy3 conjugated (Sigma-Aldrich); 1:1,000 mouse anti-
NeuN (Chemicon); 1:100 for goat anti-doublecortin (DCX)
(Santa Cruz Biotechnology, Inc.); and 1:500 for mouse antical-
bindin (Swant). To determine the number of BrdU-labeled cells, 
Qiu et al.
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Figure 1. Increased cell proliferation
in p21 /  brain tissues after MCAO.
BrdU was injected into the littermate or
age-matched p21 /  or p21 /  mice
on day 7 and 8 or day 14 and 15; and
animals were killed 9 d or 16 d after
MCAO for 20 min. Immunohistochem-
istry was performed on free-floating
40- m coronal sections pretreated by
denaturing DNA, and a specific stereo-
logical analysis (18) was applied to enu-
merate the labeled cells per volume as
detailed in Materials and Methods. A
few BrdU-labeled cells were detected in
the noninjured p21 /  and p21 /  mice.
There was an increased BrdU labeling
(black cells) in the region corresponding
to the SGZ of dentate gyrus in hippo-
campus (A) or the SVZ in lateral ventricle
(B) after MCAO. Mean values from
multiple experiments are summarized in
the graphs under each histological picture.
The noninjured samples are marked as
control in the graph. Black and white
bars indicate mean values   SD from
p21 /  and p21 /  genotype, respec-
tively. A significant increase of BrdU-
labeled cells in both genotypes and a
larger fraction of BrdU-positive cells in
p21 /  genotype was observed 9 d after
MCAO (P   0.01, n   5, assessed by
ANOVA with Bonferroni’s post hoc
analysis). To further confirm the increased
cell proliferation, the injured brain tis-
sue sections were incubated with anti-
PCNA antibody, and second antibody
was labeled with Rhodamine X (red).
The PCNA-expressing cells were sig-
nificantly more abundant in p21 / 
SVZ than in p21 /  SVZ (color pictures
in B). The color images were taken
with confocal microscopy. 
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we stained for BrdU by using the peroxidase method (ABC system,
with biotinylated horse anti–mouse IgG antibodies and diamino-
benzidine as chromogen [Vector Laboratories]). The fluorescent
secondary antibodies used were appropriate cy2- and cy3-labeled
IgG (Jackson ImmunoResearch Laboratories), 1:200 dilution. The
same stereological estimation was used to quantify the double-pos-
itive cells as described in 5-Bromodeoxyuridine Incorporation In
Vivo and Stereological Analysis. For the TUNEL assay, a well es-
tablished protocol in our laboratory was used in this study (22).
 
Enzyme Immunoassay for Fibroblast Growth Factor-2
 
For enzyme immunoassay (EIA), the brains were removed with-
out transcardial perfusion, and the hippocampi were dissected and
frozen immediately at 
 
 
 
80
 
 
 
C. Stored hippocampi were homog-
enized and centrifuged at 14,000 
 
g
 
 for 30 min at 4
 
 
 
C. Protein
concentration of each supernatant was determined by a protein
assay kit (Bio-Rad Laboratories). EIA for fibroblast growth factor
(FGF)-2 was performed by using an assay kit (Quantikine HS;
R&D Systems) according to the manufacturer’s instruction and
our previous work (19). 
 
Neurosphere Culture
 
Culture of neurospheres was based on the previously published
method (23, 24) with minor modifications. Details are provided
in Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20031385/DC1.
 
Online Supplemental Material
 
Photographic images along with culture conditions for neuro-
spheres (Fig. S1) and experimental design for the in vivo assess-
ments used in the brain ischemic model (Fig. S2) are available at
http://www.jem.org/cgi/content/full/jem.20031385/DC1.
 
Results
 
Cell Proliferation in the Neurogenic Regions Under Steady-
state (Noninjured) Conditions. We assessed cell prolifera-
tion within the subgranular zone (SGZ) of hippocampal
dentate gyrus and the SVZ of the lateral ventricle. Both
regions contain well-defined neural precursors that main-
tain ongoing low-level neurogenesis in adults (25, 26). To
directly determine the cell cycling status of the neural pre-
cursors in vivo, we examined by immunohistochemistry
the incorporation of the thymidine analogue, BrdU, into
brain cells in 8–12-wk-old mice. It has been shown previ-
ously that cycling cells in this model do not express ma-
ture neuron markers according to a defined experimental
protocol (19, 27), and therefore, BrdU incorporation in
the regions is thought to mainly reflect proliferative activ-
ity of precursor cells. BrdU uptake over 48 h was analyzed
to assess cell proliferative activity. Under steady-state con-
ditions, a low level of BrdU labeling (black cells) was de-
tected in the noninjured mice (Fig. 1). Labeled cells were
found mainly in the SGZ and SVZ as reported previously
(19). However, the numbers of BrdU-positive cells in
p21 /  and p21 /  mice did not differ significantly in ei-
ther the SGZ (Fig. 1 A) or SVZ (Fig. 1 B), unexpectedly
demonstrating no impact of p21 deletion on the prolifera-
tion of neural precursors under steady-state or noninjured
conditions. To further confirm this unexpected finding,
the neurosphere culture system (23) was used to enumer-
ate NSCs from hippocampus and lateral ventricle tissue.
Consistent with the above in vivo data, the number of
neurospheres from p21 /  mice was not significantly dif-
ferent from p21 /  mice (SGZ: 121   150 and 179  
203 in p21 /  and p21 /  mice, respectively; SVZ: 496  
163 and 501   249 in p21 /  and p21 /  mice, respec-
tively; mean   SD, n   4/each). In addition, we did not
observe significant differences in the neural or glial differ-
entiation potential of the cells regardless of the integrity
of their p21 gene locus (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20031385/DC1).
Cell Proliferation in SGZ and SVZ After Brain Ischemia.
Reasoning that the potential biological consequences of the
absence of p21 might be revealed under conditions of dam-
age stress, we exposed the animals to ischemic injury by
MCAO (16, 19; Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20031385/DC1). MCAO has been
demonstrated as an unique model in which robust neuro-
genesis can be achieved in weeks (9, 19, 28), and in this
study, we chose a mild condition during the procedure
(MCAO for 20 min) as a first attempt to assess the direct
impact of p21 absence on the proliferation of neural pre-
cursors. 1 wk after MCAO, there was an increased BrdU
incorporation in both p21 /  and p21 /  injured mice
(Fig. 1). Moreover, the increase of BrdU incorporation in
the injured animals was significantly higher in p21 /  mice
than in p21 /  mice (SGZ: 3.0- and 1.5-fold increase in
p21 /  and p21 /  mice, respectively, P   0.0003; SVZ:
3.1- and 1.4-fold increase in p21 /  and p21 /  mice, re-
spectively, P   0.0029). These differences were found at 1
wk and then interestingly reverted to the baseline 2 wk af-
ter injury in both p21 /  and p21 /  animals (Fig. 1,
graphs), indicating a specific association with the acute in-
Figure 2. Up-regulation of p21 expression in brain tissues after
MCAO. RT-PCR for p21 or GAPDH was performed on the noninjured
and injured (MCAO) tissues from hippocampus (Hipp) or subventricular
zone (SVZ) 4 d after MCAO. An enhanced intensity of p21 expression
was noted on the RT-PCR gels, and there was a significant increase of
p21 mRNA levels if normalized to the transcript of a housekeeping gene
(GAPDH) after MCAO (black bars) in both anatomic sites (two experi-
ments, two pairs of animals in each experiment) as shown in the graph.
Numbers above the gels indicate samples from different individual animals.
The noninjured samples are marked as control in the graph. Detailed
RT-PCR conditions are described in the methods.Qiu et al. 941
jury. To confirm that the BrdU incorporation indicated the
cell proliferation activity in the regions, we also examined
the proliferating cell nuclear antigen (PCNA) and found
that the PCNA-positive cells were more abundant in p21 / 
SVZ than in p21 /  SVZ after injury (Fig. 1 B, top right
panels). Therefore, cell proliferation in SGZ or SVZ is re-
sponsive to ischemic injury despite the absence of overt in-
jury to those sites (see the data in the next paragraph), and
p21 appears to limit the proliferative response to the injury.
The physiologic relevance of p21 in that context was fur-
ther supported by the up-regulation of p21 mRNA 4 d
after brain ischemia in the SGZ and SVZ regions of wild-
type animals (Fig. 2), which was consistent with the ele-
vated levels of the p21 protein reported by others (29).
Minimal Cell Death in SGZ and SVZ After MCAO.
Because SGZ and SVZ lie outside the core territory sup-
plied by the middle cerebral artery, under the mild injury
condition applied in this study, significant cell death was
not anticipated in these specific regions. To further assess
this, we then examined the tissue sections using terminal
deoxynucleotidyl transferase–mediated deoxyuridinetri-
phosphate nick end labeling (TUNEL) within the hippocam-
pus and adjacent structures after MCAO. Unlike our previ-
ous demonstration of TUNEL-positive staining in striatum
after MCAO (30), BrdU-stained cells in the SVZ and hip-
pocampus exhibited normal neuronal morphology without
morphological features of apoptosis. Further, there were no
TUNEL-positive cells observed on day 1, 2, or 9 after
MCAO in these two regions (not depicted). Response to
brain injury in an area remote from injured cells and tissue
has advantages over models in which cells themselves are
injured possibly irreparably. Relatively mild injury and dis-
tal site evaluation allowed us to more accurately quantify
cell proliferation without the confounding effects of DNA
damage, cell apoptosis, or infiltrating inflammatory cells.
Migration and Differentiation Potential of the Neural Precursor
Cells from SGZ. To explore the potential of migration
and differentiation of the precursors detected by BrdU in-
corporation, the migration marker for neurons, DCX (31,
32), and the specific marker for mature neurons, NeuN,
were used to costain the BrdU-positive cells in dentate gy-
rus of hippocampus 9 and 35 d after MCAO (Fig. S2).
Doublecortin is known to be microtubule-associated pro-
tein widely expressed in migrating and differentiating neu-
Figure 3. Expression of the neuronal migration marker (DCX)
by the proliferating cells in SGZ 1 wk after MCAO. BrdU was
injected on day 7 and 8, and animals were killed on day 9 after
MCAO. Immunohistochemistry was performed on floating 40- m
coronal sections pretreated by denaturing DNA, and a specific
stereological analysis (18) was applied to enumerate the labeled cells per volume as detailed in Materials and Methods. Brain sections were stained for
BrdU immunoreactivity (cy2, green) with the neuronal migration indicator, DCX (cy3, red) and examined in SGZ of dentate gyrus with confocal
microscopy for BrdU/DCX-coexpressing cells (merged, yellow) (A). A significant increase of BrdU/DCX double-positive cells in p21 /  SGZ espe-
cially after MCAO was visualized among the different samples (B). The morphology of the neuroblast cell expressing both BrdU and DCX is shown by
a single cell in two-dimension (C) and three-dimension (D). Based on the data from multiple experiments, these differentiating cells positive for DCX/BrdU
are significantly more in p21 /  SGZ than in p21 /  SGZ (P   0.01, n   4, assessed by ANOVA with Bonferroni’s post hoc analysis) (E). The black
and white bars in the graphs indicate mean values   SD from the p21 /  and p21 /  genotype, respectively. The noninjured samples are marked as
control and Day 9 indicates 9 d after MCAO in the graph (E).p21 and Neural Stem Cells 942
rons (32, 33). We found that the DCX-positive cells were
mainly located in SGZ. The majority (96%) of BrdU-posi-
tive cells in the region acquired the expression of DCX and
had the morphological characteristic of the neuroblast cell
1 d after the 2-d BrdU injection procedure (Fig. 3, A–C).
The increase of DCX/BrdU double-positive cells corre-
lated with the increase of BrdU incorporation after injury,
indicating that these neuroblast cells were immediate prog-
enies of the activated precursors and, moreover, that there
was a higher abundance of the neural precursors generated
in p21 /  brain after injury (Fig. 3, D and E). The precur-
sor nature of the BrdU-incorporated cells shortly after in-
jury was further confirmed by the absence of NeuN in the
BrdU-positive cells in SGZ 9 d after MCAO (1 d after the
2-d BrdU injection procedure) (Fig. 4 A, first column).
Subsequently, to reveal a further differentiating phenotype,
separate groups of animals injected with BrdU at day 7 and
8 after injury or no injury were maintained for an addi-
tional 4 wk. Brain sections were stained for BrdU (cy2,
green) plus neuronal or glial markers (cy3, red) and exam-
ined with confocal microscopy. Colocalization of the glial
marker GFAP with BrdU was rarely observed in steady-
state or ischemic conditions in the regions, but a majority
(82–93%) of the survived BrdU-marked cells on the first
week after MCAO had migrated from SGZ to GCL and
were positive for NeuN (Fig. 4 A, second and third col-
umns) during the additional 4 wk. There was an increase of
NeuN/BrdU-costained cells at this later time point after
injury in all groups. Strikingly, after injury the number of
BrdU/NeuN-costained cells was significantly higher in
p21 /  mice than in the p21 /  littermates (5.6-fold in-
crease in p21 /  mice and 1.9-fold increase in p21 / 
mice, P   0.0001) (Fig. 4 B). In addition, the expression of
a distinct marker for mature neurons, calbindin (21), fur-
ther confirmed the maturation of the neuron-like cells as
the coexpression of calbindin with BrdU was similar to that
of NeuN in the cells. Notably, unlike NeuN/BrdU coex-
pression, DCX BrdU  cells appearing earlier after MCAO
were not present in GCL at this later time point, which is
consistent with the recent study by others (34). Together,
these data strongly demonstrate a significant impact of p21
on the regeneration of the neuron-like cells from their pre-
cursors after brain ischemia.
Independent Effect of p21 from the Known Upstream Regula-
tors. p21 has been demonstrated to be transcriptionally
up-regulated by p53 upon DNA damage (35), and we
sought to functionally determine whether the restriction of
p21 on neural regeneration after brain ischemia is depen-
dent on the presence of p53. Thus, we examined BrdU in-
corporation before and after MCAO in p53 /  mice com-
pared with p53 /  controls (Fig. 5). In contrast to p21 / 
and p21 /  animals, there was no difference in BrdU in-
corporation between p53 /  and p53 / , although an in-
crease in BrdU incorporation after ischemia was observed
(n   5/group). Therefore, the inhibitory role of p21 in
neural proliferation in vivo appears to be independent of
p53. Further, to rule out that the increased proliferation in
the absence of p21 after ischemia may be due to elevated
levels of some key neural growth factors in p21-null ani-
mals, we measured the concentrations of FGF-2 and epi-
dermal growth factor (EGF) in hippocampus 1 wk after in-
jury (19). FGF-2 and EGF have been shown to be potent
Figure 4. Expression of the neuronal maturation markers
(NeuN and Calbindin) by the proliferated cells in GCL 5 wk
after MCAO. BrdU was injected on day 7 and 8, and animals
were killed on day 9 or 35 after MCAO. Brain sections
were stained for BrdU immunoreactivity (cy2, green) and
the neuronal differentiation marker (cy3, red) NeuN (A)
or calbindin (C) and examined with confocal microscopy.
Immunohistochemistry was performed on floating 40- m
coronal sections pretreated by denaturing DNA and a specific
stereological analysis (18) was applied to enumerate the
labeled cells per volume as detailed in Materials and
Methods. NeuN was extensively examined on day 9 and
35 after MCAO. 9 d after MCAO, most BrdU-positive
cells in SGZ did not express NeuN (A, first column).
Strikingly, 35 d after MCAO a significant increase of
BrdU/NeuN double-positive cells in both genotypes and
a larger fraction of BrdU/NeuN-positive cells in p21 / 
brain was observed and relocated from SGZ to GCL after
MCAO (P   0.01, n    5, assessed by ANOVA with
Bonferroni’s post hoc analysis) (A and B). The black and
white bars in the graphs indicate mean values   SD from
p21 /  and p21 /  genotype, respectively. The nonin-
jured samples are marked as control and MCAO indicates
35 d after MCAO in the graph. Calbindin was used as an
independent differentiation marker showing its coexpres-
sion in with BrdU in the cells located in GCL 35 d after
injury (C, merged yellow color a representative image
from the p21 /  brain).Qiu et al. 943
mitogens stimulating the proliferation of NSC and NPC
from adult brain. FGF-2 was able to stimulate in vivo neu-
rogenesis through a systemic injection (36), and in particu-
lar we demonstrated recently that FGF-2 delivery by viral
vector promotes neurogenesis in the SGZ after brain isch-
emia (19). We in this study that the levels of FGF-2 were
increased after injury, as we reported previously (19), but
there was no difference between p21 /  and p21 /  ani-
mals (Fig. 6). In agreement with a previous report that EGF
has no proliferative effect in the SGZ in vivo (7), EGF was
not detectable at the protein level in SGZ after MCAO
(unpublished data), likely due to location or development
stage–dependent expression of EGF (37). Admittedly, our
data cannot exclude influences from other potential neural
growth factors yet to be defined. Nevertheless, these data
suggest that p21 promotes proliferation of NSC and NPC
in adult brain independent of raised levels of the essential
growth factors of EGF and FGF-2.
Discussion
This study provides the first evidence that cell cycle acti-
vation of neural precursors in vivo is intrinsically inhibited
by p21 after brain injury, through a p53-independent path-
way. Similar responses in both hippocampus and lateral
ventricle indicate that the effect of p21 is not highly loca-
tion specific. In the mild and remote injury model we used,
hippocampal cells were stressed as a result of focal ischemia
and were stimulated to divide, similar to periventricular
cells. It is anticipated that these cells may not only partici-
pate in the recovery process after focal ischemia but also
provide a source of cells potentially renewable for repairing
injured striatal tissue, especially in the light of the recent
studies demonstrating the migration of the neural precur-
sors from SVZ to the injured sites after severe brain isch-
emia (9, 10). Therefore, this study provides a rationale for
future strategies to suppress p21 within injured brain after
severe ischemia.
It is unlikely that the BrdU-positive cells were the result
of DNA repair rather than proliferation based on the fol-
lowing reasons: (a) the documented intensity and location
of the BrdU staining specific for neural cell proliferation
was consistent with the previous validations by others (7,
19, 28); (b) the “off-on” coexpression of NeuN with BrdU
suggested neuronal differentiation; (c) there was a minimal
degree of cell apoptosis or inflammatory response in the re-
gions; and (d) there was a correlated appearance of the in-
dependent indicator for cell proliferation, PCNA, with
BrdU incorporation. Arguably, it might be possible that the
increased BrdU incorporation in the p21 /  injured brain
may reflect the reentry into cell cycle of some postmitotic
differentiated cells as demonstrated in the p27 /  or p19 / 
mice (38). However, the fact that BrdU-incorporated
cells exhibited little coexpression of NeuN 1 wk and ac-
quired NeuN later on after injury opposes the possibility of
“dedifferentiation” of the postmitotic differentiated cells. In
addition, it might be also possible that abnormal alterations
in cell cycle kinetics, as mediated by the absence of p21,
may alter the neural fate choices or downstream differentia-
tion potential in the way that would contribute to the
composition of cell subtypes in the regenerated tissue as a
result of the experimental ischemic insult. Although this is-
sue perhaps needs formal exploration within CNS in the
Figure 5. No difference of the cell proliferation in SGZ between
p53 /  and p53 /  mice. Identical methods were used as described in the
study on BrdU incorporation in p21 /  or p21 /  mice (Fig. 1), and
there was no difference of BrdU incorporation between p53 /  and
p53 /  in SGZ either before or after MCAO (P   0.05, n = 5, assessed
by ANOVA with Bonferroni’s post hoc analysis). Mean values from mul-
tiple experiments are summarized in the graph under the histological pic-
ture. White and black bars in the graphs indicate mean values   SD from
p53 /  and p53 /  genotype, respectively. The noninjured samples are
marked as control in the graph.
Figure 6. No difference in the levels of FGF-2 growth factor in hippo-
campus between p21 /  and p21 /  mice. FGF-2 concentration in
hippocampus before and 1 wk after MCAO was measured by EIA as
described in Materials and Methods. Black and white bars in the graph
indicate mean values   SD from p21 /  and p21 /  samples, respec-
tively. Five animals in each group were used in this experiment.p21 and Neural Stem Cells 944
future, we did not observe the altered lineage distribution
in the neurosphere culture system in the absence of p21
(Fig. S1), arguing against the possibility.
Our study provides intriguing parallels with the role of
p21 in stem cell regulation in hematopoietic tissue (14). A
functional parallelism between neurogenesis and hemato-
poiesis has been proposed to map the hierarchy of neural
precursor cells. This has been partially substantiated by the
studies suggesting transdifferentiation (39–41) and shared
gene transcripts between these two stem cell populations
(42–45). Together with our previous work in both mouse
and human HSCs (14, 46), we present a functional ap-
proach, defining a common cell cycle mediator restricting
cell cycle entry in primitive quiescent cells from different
tissues. Of note, we did not observe an increase of NSC/
NPC proliferation in p21 /  mice under homeostatic con-
ditions, which contrasts with the increased stem cell number
and more active cell cycling status we observed in hemato-
poiesis (14). Several reasons might account for this differ-
ence. First, there are fundamental differences between
neurogenesis and hematopoiesis in the turnover rate and
longevity of newly born cells. The demand for steady-state
proliferation of neural precursors in CNS is much lower
than in the hematopoietic system. Second, possible com-
pensation from other CKIs or other molecules in p21 / 
mice might contribute to the invisible change of NSC pro-
liferation under noninjured conditions. However, data indi-
cating that p21-null and p27- or p18-null have very differ-
ent phenotypes in ischemic brain (unpublished data), similar
to what we found in the hematopoietic system (13), does
not seem to support the possibility. Third, it is possible that
altered BrdU incorporation cannot be specifically detected
in NSC due to the lack of our ability to phenotypically
distinguish NSC from NPC in vivo. Notably, a distinct
temporal pattern of increasing NeuN/BrdU double-posi-
tive cells was observed in the p21-null setting in the cur-
rent study (Fig. 4 B). After MCAO, there were 3.0-fold
increases of single BrdU-positive cells at 1 wk that in-
creased to a 5.6-fold increase of BrdU/NeuN double-pos-
itive cells at 1 mo. This magnitude of rise over time was
smaller in the p21 /  animals where the increases were
1.5–1.9, respectively, thereby suggesting that the absence
of p21 may have engaged a more primitive, self-expanding
population of stem cells. This speculation is supported by a
recent study indicating a possible role of p21 in regulat-
ing NSC self-renewal caused by the Bmi-1 protein (47),
whereas further proof of this possibility awaits a clear phe-
notype of NSC in vivo equivalent to that defined for HSC
(48).
In conclusion, p21 appears to specifically restrict entry of
quiescent precursors into cell cycle in both adult neural and
hematopoietic tissue types despite the distinct proliferative
kinetics of the two systems. Functionally similar HSC,
NSC/NPC, and possibly other stem cell type (49) may
share the molecular commonality of p21-restricted cell
proliferation. As a corollary, altering p21 expression may be
viewed as a possible means of enhancing stem cell response
to tissue injury in general.
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